Concepts (291)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 19 | 2022 | 448 | 6.270 |
Why?
|
| Periodontal Diseases | 10 | 2021 | 54 | 2.440 |
Why?
|
| Bayes Theorem | 14 | 2022 | 307 | 1.990 |
Why?
|
| Computer Simulation | 22 | 2022 | 706 | 1.660 |
Why?
|
| Biometry | 5 | 2017 | 72 | 1.550 |
Why?
|
| Linear Models | 7 | 2021 | 521 | 1.160 |
Why?
|
| Markov Chains | 10 | 2020 | 133 | 1.110 |
Why?
|
| Periodontitis | 2 | 2021 | 47 | 1.090 |
Why?
|
| Biostatistics | 4 | 2020 | 43 | 1.050 |
Why?
|
| Data Interpretation, Statistical | 9 | 2019 | 329 | 0.980 |
Why?
|
| Likelihood Functions | 9 | 2021 | 106 | 0.840 |
Why?
|
| Maximum Tolerated Dose | 2 | 2012 | 41 | 0.790 |
Why?
|
| Dental Caries | 3 | 2013 | 40 | 0.790 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 26 | 0.790 |
Why?
|
| Tooth | 2 | 2021 | 24 | 0.790 |
Why?
|
| Refraction, Ocular | 2 | 2012 | 61 | 0.760 |
Why?
|
| Monte Carlo Method | 8 | 2020 | 124 | 0.730 |
Why?
|
| Algorithms | 7 | 2020 | 1196 | 0.670 |
Why?
|
| Body Mass Index | 6 | 2020 | 867 | 0.670 |
Why?
|
| Mouth Neoplasms | 2 | 2021 | 206 | 0.670 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2017 | 1085 | 0.670 |
Why?
|
| Humans | 59 | 2022 | 68618 | 0.660 |
Why?
|
| Pediatric Obesity | 1 | 2020 | 92 | 0.650 |
Why?
|
| Health Status | 2 | 2020 | 429 | 0.600 |
Why?
|
| Cocaine-Related Disorders | 3 | 2011 | 504 | 0.550 |
Why?
|
| Aging | 2 | 2020 | 911 | 0.530 |
Why?
|
| Cluster Analysis | 6 | 2021 | 219 | 0.530 |
Why?
|
| Thinness | 1 | 2015 | 14 | 0.510 |
Why?
|
| Oral Health | 6 | 2013 | 49 | 0.500 |
Why?
|
| Viral Load | 2 | 2012 | 127 | 0.490 |
Why?
|
| Normal Distribution | 5 | 2021 | 46 | 0.470 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2012 | 152 | 0.450 |
Why?
|
| Dementia | 1 | 2015 | 158 | 0.450 |
Why?
|
| Obesity | 3 | 2018 | 1076 | 0.420 |
Why?
|
| Male | 37 | 2021 | 37321 | 0.400 |
Why?
|
| Pseudophakia | 1 | 2012 | 27 | 0.400 |
Why?
|
| Myopia | 1 | 2012 | 27 | 0.400 |
Why?
|
| Aphakia | 1 | 2011 | 7 | 0.400 |
Why?
|
| Female | 36 | 2020 | 38074 | 0.390 |
Why?
|
| Behavioral Research | 1 | 2011 | 10 | 0.390 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 848 | 0.380 |
Why?
|
| Regression Analysis | 6 | 2019 | 737 | 0.370 |
Why?
|
| Lenses, Intraocular | 1 | 2011 | 96 | 0.370 |
Why?
|
| HIV-1 | 1 | 2012 | 177 | 0.370 |
Why?
|
| Blood Glucose | 2 | 2012 | 631 | 0.360 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 148 | 0.360 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 1046 | 0.360 |
Why?
|
| Gingival Crevicular Fluid | 1 | 2009 | 9 | 0.350 |
Why?
|
| Models, Immunological | 1 | 2009 | 25 | 0.350 |
Why?
|
| Nursing Administration Research | 1 | 2009 | 7 | 0.340 |
Why?
|
| Direct Service Costs | 1 | 2009 | 8 | 0.340 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 805 | 0.330 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2009 | 64 | 0.330 |
Why?
|
| Nursing Staff, Hospital | 1 | 2009 | 62 | 0.320 |
Why?
|
| Middle Aged | 25 | 2020 | 21147 | 0.320 |
Why?
|
| Workload | 1 | 2009 | 103 | 0.310 |
Why?
|
| Data Collection | 1 | 2009 | 420 | 0.300 |
Why?
|
| Research Design | 3 | 2021 | 729 | 0.290 |
Why?
|
| Graft Rejection | 3 | 2020 | 458 | 0.280 |
Why?
|
| Least-Squares Analysis | 2 | 2021 | 35 | 0.280 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 306 | 0.280 |
Why?
|
| Kidney Transplantation | 3 | 2020 | 839 | 0.280 |
Why?
|
| Adult | 20 | 2021 | 21403 | 0.270 |
Why?
|
| Liver Transplantation | 2 | 2020 | 400 | 0.260 |
Why?
|
| Periodontal Attachment Loss | 3 | 2017 | 12 | 0.260 |
Why?
|
| Models, Biological | 1 | 2009 | 981 | 0.260 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1054 | 0.260 |
Why?
|
| Cytokines | 1 | 2009 | 866 | 0.250 |
Why?
|
| Quality of Life | 2 | 2014 | 1515 | 0.240 |
Why?
|
| Alcoholism | 2 | 2013 | 1109 | 0.240 |
Why?
|
| Smoking | 5 | 2015 | 1452 | 0.240 |
Why?
|
| United States | 13 | 2021 | 7367 | 0.240 |
Why?
|
| Poisson Distribution | 3 | 2013 | 85 | 0.220 |
Why?
|
| South Carolina | 7 | 2012 | 2752 | 0.220 |
Why?
|
| Sex Factors | 6 | 2011 | 1266 | 0.220 |
Why?
|
| Age Factors | 6 | 2018 | 1864 | 0.210 |
Why?
|
| Aged | 16 | 2019 | 14862 | 0.210 |
Why?
|
| Cross-Sectional Studies | 8 | 2015 | 2279 | 0.210 |
Why?
|
| Registries | 4 | 2018 | 733 | 0.210 |
Why?
|
| Tissue and Organ Procurement | 3 | 2020 | 164 | 0.200 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 792 | 0.200 |
Why?
|
| Blood Pressure | 2 | 2020 | 1451 | 0.180 |
Why?
|
| Menarche | 1 | 2020 | 18 | 0.180 |
Why?
|
| Research Subjects | 2 | 2011 | 45 | 0.180 |
Why?
|
| Juvenile Delinquency | 2 | 2012 | 129 | 0.170 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 208 | 0.170 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 211 | 0.170 |
Why?
|
| Tissue Donors | 2 | 2018 | 195 | 0.170 |
Why?
|
| Databases, Factual | 3 | 2019 | 622 | 0.160 |
Why?
|
| Adolescent | 7 | 2020 | 8912 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2019 | 300 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 504 | 0.160 |
Why?
|
| Liver Failure | 1 | 2018 | 27 | 0.160 |
Why?
|
| Sex Offenses | 2 | 2012 | 170 | 0.160 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 2800 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1745 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2010 | 1040 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 121 | 0.150 |
Why?
|
| Retrospective Studies | 8 | 2020 | 7277 | 0.140 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 951 | 0.140 |
Why?
|
| Hepacivirus | 1 | 2017 | 90 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 561 | 0.140 |
Why?
|
| Logistic Models | 4 | 2013 | 1420 | 0.140 |
Why?
|
| Comorbidity | 4 | 2020 | 1426 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 299 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 454 | 0.130 |
Why?
|
| Software | 2 | 2019 | 418 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2017 | 114 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 514 | 0.130 |
Why?
|
| Chronic Periodontitis | 2 | 2013 | 18 | 0.130 |
Why?
|
| Cues | 2 | 2011 | 654 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 475 | 0.130 |
Why?
|
| Taurine | 2 | 2013 | 51 | 0.130 |
Why?
|
| Disease Progression | 4 | 2013 | 1038 | 0.130 |
Why?
|
| Alcohol Deterrents | 2 | 2013 | 86 | 0.120 |
Why?
|
| Child | 5 | 2013 | 6405 | 0.120 |
Why?
|
| Carcinogens | 1 | 2015 | 86 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 772 | 0.120 |
Why?
|
| Young Adult | 4 | 2018 | 5717 | 0.120 |
Why?
|
| Toothbrushing | 2 | 2011 | 21 | 0.120 |
Why?
|
| Tobacco Use | 1 | 2015 | 98 | 0.120 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2014 | 20 | 0.120 |
Why?
|
| Tobacco | 1 | 2015 | 161 | 0.120 |
Why?
|
| Naltrexone | 2 | 2013 | 195 | 0.120 |
Why?
|
| Gingival Hemorrhage | 2 | 2011 | 10 | 0.110 |
Why?
|
| Periodontal Pocket | 2 | 2011 | 15 | 0.110 |
Why?
|
| Space-Time Clustering | 1 | 2013 | 15 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 649 | 0.110 |
Why?
|
| Risk Factors | 5 | 2018 | 5731 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2009 | 694 | 0.110 |
Why?
|
| Self Report | 1 | 2015 | 371 | 0.110 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2012 | 18 | 0.110 |
Why?
|
| Esthetics, Dental | 1 | 2012 | 37 | 0.100 |
Why?
|
| Time Factors | 4 | 2017 | 4655 | 0.100 |
Why?
|
| Criminals | 1 | 2012 | 26 | 0.100 |
Why?
|
| Retinoscopy | 1 | 2012 | 11 | 0.100 |
Why?
|
| Axial Length, Eye | 1 | 2012 | 15 | 0.100 |
Why?
|
| Recurrence | 2 | 2012 | 948 | 0.100 |
Why?
|
| Substance-Related Disorders | 2 | 2011 | 1242 | 0.100 |
Why?
|
| Graft Survival | 3 | 2020 | 465 | 0.100 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2011 | 20 | 0.100 |
Why?
|
| Sleep | 1 | 2014 | 263 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 123 | 0.100 |
Why?
|
| Myofunctional Therapy | 1 | 2011 | 6 | 0.100 |
Why?
|
| Gingivitis | 1 | 2011 | 16 | 0.100 |
Why?
|
| Dental Devices, Home Care | 1 | 2011 | 17 | 0.100 |
Why?
|
| Needs Assessment | 2 | 2010 | 186 | 0.100 |
Why?
|
| Substance Abuse Detection | 1 | 2011 | 66 | 0.100 |
Why?
|
| Nonlinear Dynamics | 1 | 2011 | 55 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 3259 | 0.090 |
Why?
|
| Statistical Distributions | 1 | 2010 | 8 | 0.090 |
Why?
|
| Root Caries | 1 | 2010 | 5 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2013 | 191 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2013 | 880 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 53 | 0.090 |
Why?
|
| Disease | 1 | 2010 | 41 | 0.090 |
Why?
|
| Dental Care for Disabled | 1 | 2010 | 8 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2010 | 104 | 0.090 |
Why?
|
| Bias | 1 | 2011 | 148 | 0.090 |
Why?
|
| DMF Index | 1 | 2009 | 1 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2011 | 99 | 0.090 |
Why?
|
| Attitude to Health | 2 | 2010 | 403 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2077 | 0.090 |
Why?
|
| Marijuana Smoking | 1 | 2011 | 108 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2017 | 1615 | 0.090 |
Why?
|
| Benzo(a)pyrene | 1 | 2009 | 7 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 11 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 425 | 0.090 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2009 | 14 | 0.080 |
Why?
|
| Ethylene Glycol | 1 | 2009 | 4 | 0.080 |
Why?
|
| Behavior Therapy | 1 | 2012 | 297 | 0.080 |
Why?
|
| Time and Motion Studies | 1 | 2009 | 16 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2018 | 7029 | 0.080 |
Why?
|
| Prognosis | 3 | 2020 | 2093 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2011 | 201 | 0.080 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2009 | 29 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 60 | 0.080 |
Why?
|
| Resource Allocation | 1 | 2009 | 35 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2012 | 384 | 0.080 |
Why?
|
| Criminal Law | 1 | 2009 | 30 | 0.080 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2009 | 92 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2011 | 586 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2011 | 296 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 189 | 0.080 |
Why?
|
| Drug-Seeking Behavior | 1 | 2011 | 213 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 498 | 0.080 |
Why?
|
| Decision Making | 1 | 2011 | 410 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2009 | 215 | 0.080 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2007 | 7 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2011 | 2358 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 362 | 0.070 |
Why?
|
| Scleroderma, Systemic | 1 | 2011 | 446 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2009 | 652 | 0.070 |
Why?
|
| Automobile Driving | 1 | 2007 | 88 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 800 | 0.070 |
Why?
|
| Hypertension | 2 | 2013 | 1535 | 0.070 |
Why?
|
| Behavior, Addictive | 1 | 2009 | 317 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 1056 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2011 | 665 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 581 | 0.060 |
Why?
|
| Psychometrics | 3 | 2014 | 514 | 0.060 |
Why?
|
| Income | 3 | 2011 | 167 | 0.060 |
Why?
|
| Infant | 1 | 2011 | 2891 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2011 | 824 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2011 | 3187 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 629 | 0.060 |
Why?
|
| Spinal Cord Injuries | 1 | 2010 | 551 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 767 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 274 | 0.060 |
Why?
|
| Incidence | 2 | 2020 | 1603 | 0.060 |
Why?
|
| HIV Infections | 1 | 2011 | 791 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 2 | 2014 | 201 | 0.050 |
Why?
|
| Stochastic Processes | 1 | 2021 | 27 | 0.050 |
Why?
|
| Insurance, Dental | 2 | 2010 | 11 | 0.040 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 60 | 0.040 |
Why?
|
| Educational Status | 2 | 2010 | 273 | 0.040 |
Why?
|
| Employment | 2 | 2010 | 154 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2018 | 64 | 0.040 |
Why?
|
| Stroke | 1 | 2011 | 2163 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 125 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 153 | 0.040 |
Why?
|
| Diabetes Complications | 2 | 2010 | 249 | 0.040 |
Why?
|
| Adolescent Behavior | 2 | 2012 | 264 | 0.040 |
Why?
|
| Brachytherapy | 1 | 2018 | 79 | 0.040 |
Why?
|
| Medicaid | 2 | 2011 | 302 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 114 | 0.040 |
Why?
|
| Overweight | 1 | 2018 | 186 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 365 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2018 | 172 | 0.030 |
Why?
|
| Minnesota | 1 | 2015 | 27 | 0.030 |
Why?
|
| Belgium | 1 | 2013 | 18 | 0.030 |
Why?
|
| Dentists | 1 | 2013 | 18 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 2013 | 21 | 0.030 |
Why?
|
| Temperance | 1 | 2013 | 41 | 0.030 |
Why?
|
| Sweden | 1 | 2012 | 21 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 94 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 2007 | 0.030 |
Why?
|
| Public Policy | 1 | 2012 | 71 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2012 | 71 | 0.030 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 1 | 2011 | 19 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2013 | 184 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2013 | 210 | 0.020 |
Why?
|
| Dental Plaque Index | 1 | 2011 | 10 | 0.020 |
Why?
|
| Mouth Rehabilitation | 1 | 2011 | 7 | 0.020 |
Why?
|
| Gingiva | 1 | 2011 | 34 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 279 | 0.020 |
Why?
|
| Hypoalbuminemia | 1 | 2010 | 9 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2012 | 281 | 0.020 |
Why?
|
| Oral Hygiene | 1 | 2011 | 33 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2011 | 120 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 195 | 0.020 |
Why?
|
| Dental Anxiety | 1 | 2010 | 5 | 0.020 |
Why?
|
| Dental Prophylaxis | 1 | 2010 | 7 | 0.020 |
Why?
|
| Architectural Accessibility | 1 | 2010 | 8 | 0.020 |
Why?
|
| Paraplegia | 1 | 2010 | 28 | 0.020 |
Why?
|
| Wheelchairs | 1 | 2010 | 16 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 546 | 0.020 |
Why?
|
| Quadriplegia | 1 | 2010 | 29 | 0.020 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2010 | 73 | 0.020 |
Why?
|
| Pain | 1 | 2014 | 472 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2011 | 99 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 245 | 0.020 |
Why?
|
| Methylphenidate | 1 | 2011 | 97 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 411 | 0.020 |
Why?
|
| Self Concept | 1 | 2010 | 132 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 500 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2011 | 183 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2009 | 51 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 83 | 0.020 |
Why?
|
| Prisons | 1 | 2009 | 18 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1619 | 0.020 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 221 | 0.020 |
Why?
|
| Forensic Psychiatry | 1 | 2009 | 36 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 782 | 0.020 |
Why?
|
| Medicare | 1 | 2011 | 319 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 492 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1738 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2010 | 346 | 0.020 |
Why?
|
| Reaction Time | 1 | 2007 | 170 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1753 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2007 | 230 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 213 | 0.020 |
Why?
|
| Crime Victims | 1 | 2009 | 286 | 0.020 |
Why?
|
| Attention | 1 | 2007 | 225 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 4848 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2007 | 1342 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 8474 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 20881 | 0.010 |
Why?
|